Lilly to Buy Merida for $2.875B

Eli Lilly has agreed to acquire Merida Biosciences for up to $2.875 billion in cash, expanding its pipeline of potential treatments for immunity-related and allergic diseases. The deal includes an upfront payment and milestone-based payments, and is expected to close in the fourth quarter of 2026.

Merida's lead candidate, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease, and has shown substantial reductions in disease-related antibodies and a favorable initial safety profile in early Phase 1 data. The company's pipeline also includes MER769, an experimental treatment for food allergy, asthma, and other allergic diseases.

The acquisition is part of Eli Lilly's strategy to expand its pipeline beyond obesity and diabetes. The company has been on an acquisition spree in 2026, with the Merida deal being the latest addition to its expanding pipeline. Francisco Ramírez-Valle, senior vice president of Lilly immunology research and early clinical development, stated that the company is building its pipeline around therapies that meaningfully change the course of disease.

Adam Townsend, chief executive officer of Merida, stated that joining Lilly gives Merida's science the resources and commitment to realize its potential for patients with immune-mediated conditions. The acquisition gives Eli Lilly access to Merida's antibody-engineering platform, which is designed to selectively eliminate disease-causing autoantibodies while preserving normal immune function.

## Why it matters The deal is significant for Eli Lilly as it diversifies its pipeline and reduces its reliance on the obesity and diabetes markets. The acquisition also highlights the company's focus on developing targeted treatments for autoimmune and allergic diseases. With Merida's technology, Eli Lilly may be able to offer more targeted treatment strategies and create opportunities across several conditions.

The acquisition is also a testament to the growing importance of immunology in the pharmaceutical industry. As companies like Eli Lilly continue to invest in this area, we can expect to see more innovative treatments for immunity-related and allergic diseases. With the deal expected to close in the fourth quarter of 2026, Eli Lilly is poised to make a significant impact in the immunology space.

## What happens next The acquisition is subject to closing conditions and is expected to be completed in the fourth quarter of 2026. Once the deal is finalized, Eli Lilly will have access to Merida's pipeline and technology, and will be able to further develop the company's lead candidate, MER511. As the company continues to expand its pipeline, we can expect to see more updates on the development of Merida's treatments and their potential impact on the pharmaceutical industry.